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ABSTRAK 
 
Latar Belakang Kajian 
Barah mulut / Oral squamous cell carcinoma (OSCC) mempunya prognosa yang agak buruk 
kerana pesakit sering diberi diagnosis pada peringkat barah yang lanjut. Kajian terbaru telah 
menerokai penggunaan serum petanda tumor seperti Beta 2 Microglobulin (B2M) untuk 
membantu di dalam membuat diagnosis awal. Walaupun terdapat banyak kes OSCC di Asia 
Tenggara, namun tiada kajian yang dilaksanakan mengenai penggunaan klinikal B2M di rantau 
ini.  
Objektif Kajian: 
Mengenal pasti jikalau serum B2M dapat digunakan sebagai alat diagnostik awal, dan memberi 
indikasi jikalau biopsi perlu dilaksanakan. Seterusnya, kajian ini ingin mencadangkan nilai 
rujukan serum B2M setempat untuk mengenalpasti pesakit-pesakit OSCC. 
Metodologi 
Seramai dua puluh satu orang pesakit dan dua puluh satu orang sampel kawalan yang sihat 
telah mengambil bahagian di dalam kajian ini di Hospital Universiti Sains Malaysia (HUSM) 
dalam tempoh satu tahun iaitu di antara Jun 2016 sehingga Jun 2017. Selain daripada latar 
belakang dan sejarah pesakit, sebanyak 5ml darah telah diambil daripada saluran darah setiap 
pesakit pada pra-rawatan dan telah dianalisis melalui kaedah immunoturbidometry 
menggunakan ARCHITECT c800 Analyser.  Keputusan kajian telah dianalisa menggunakan 
analisis ROC dan ujian Mann Whitney.  
Keputusan:  
vi 
 
Tahap serum B2M adalah signifikan (p<0.001) di kalangan pesakit-pesakit berbanding sampel 
kawalan. Ujian tersebut mempunyai peratus sensitiviti dan spesifikasi yang sama iaitu 
sebanyak 90.5%.  Untuk membezakan kes-kes daripada sampel kawalan, tahap B2M yang telah 
dikenalpasti sebagai serum penanda tumor yang sensitif dan spesifik adalah pada nilai 
1.57mg/l.  
Kesimpulan: 
B2M ialah petanda serum tumor yang sensitif dan khusus untuk membezakan kes-kes daripada 
sampel kawalan. Memandangkan petanda tumor ini kos efektik dan kurang invasive, maka ia 
berpotensi sebagai alat diagnostik tambahan yang berguna bagi kumpulan pesakit berisiko 
tinggi. 
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ABSTRACT  
Background 
The delay in diagnosis of oral squamous cell carcinoma (OSCC) is a factor in rendering the 
poor prognosis, and recent research has explored the use of serum tumour markers such Beta 
2 Microglobulin (B2M), to aid early diagnosis. However, despite a high incidence of OSCC in 
Southeast Asia, no studies on the clinical use of B2M in the region were found. 
 Objectives: 
To determine if serum B2M level can serve as an initial diagnostic tool to indicate if a biopsy 
is warranted, and if so, to propose a local B2M serum reference value to identify OSSC patients 
Methodology: 
Twenty-one patients diagnosed with OSCC were seen at Hospital Universiti Sains Malaysia 
(HUSM) over a one-year period, between June 2016 and June 2017, and an equal number of 
healthy controls participated in the study. Apart from patient history, venous blood of 
approximately 5ml volume was collected from each subject at the pre-treatment stage and 
analysed by an Abbot ARCHITECT c8000 analyser using the immunoturbidometry 
method.The results were analysed using ROC analysis and the Mann Whitney test.  
Results:  
Serum B2M levels showed a statistically significant increase (p<0.001) in patients compared 
to controls. The test was shown to have 90.5% sensitivity and 90.5% specificity. It was found 
to be a sensitive and specific serum tumour marker at a cut off value of 1.57 mg/l to differentiate 
cases from controls.  
Conclusion: 
B2M is a sensitive and specific tumour marker to differentiate OSCC cases from controls. It is 
cost effective and minimally invasive, making it a potentially useful adjunct diagnostic tool in 
a high-risk patient pool. 
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INTRODUCTION 
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1.1 INTRODUCTON 
Oral cancer is defined as a malignant neoplasm arising from oral cavity or oropharynx; 
and commonly involves sub-sites such as the anterior two thirds of the tongue, tonsils, upper 
and lower alveolar ridge, buccal mucosa, and the hard palate [1]. Oral cancer is the 6th most 
common cancer in the world but shows wide geographical variation, but a higher incidence has 
been noted in South and Southeast Asian countries such as India, Bangladesh, Taiwan, and Sri 
Lanka [2]. Squamous cell carcinoma constitutes about 90% of oral malignancies with tumours 
arising from minor salivary glands accounting for a further 5% [1].   
Local epidemiology data from the 2007 National Cancer Registry in Malaysia reported 
a total of 353 cases of oral cancer; it was ranked as the as the 21st most common cancer in the 
general population; the 17th most common among males and the 16th most common among 
females. Furthermore, only 35.4% of the 205 cases reported with staging were of stages I and 
II [3]. Oral squamous cell carcinoma (OSCC) is characterised by a high rate of metastasis, 
recurrence, and second malignancy; with a poor prognosis [4, 5]. The 5-year survival rate for 
OSCC is approximately 50% and has remained so for the past several decades [6]. This lack of 
improvement is attributed to the fact that a large number of cases are diagnosed at an advanced 
stage. The prognosis of patients with early treatment is much better, with 5-year survival rates 
as high as 80% [7]. Thus, early detection becomes vital. 
OSCC is a multifactorial disease, and the risk factors include smoking, alcohol 
consumption, betel quid chewing, poor oral hygiene and diet and nutritional deficiencies, 
especially in vitamin A, C, E, iron, selenium, folate and phosphate. Other factors such as human 
papilloma virus (HPV) infection and premalignant conditions such as leukoplakia and 
erythroplakia have also been shown to influence the pathogenesis of OSCC [1]. 
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 Clinical oral examination (COE) is the gold standard for the initial detection of 
dysplastic or malignant oral lesions at an early stage, with confirmation by biopsy and 
histopathological examination (HPE). However, a recent systematic review concluded that the 
overall performance of COE as a diagnostic method for predicting dysplasia and OSCC has 
been poor [8]. HPE is a time-consuming process, requiring several days to fix, embed and stain 
the biopsy specimen [9]. The specimen can also be affected by artefacts resulting from 
crushing, incorrect fixation and freezing [10]. Furthermore, the biopsy process is invasive in 
nature and can pose technical difficulties to the clinician when lesions are extensive, as the 
most representative areas must be selected to avoid diagnostic errors [11]. As such, the 
proportion of OSCC cases diagnosed at an early and localised stage is still <50% within a 5-
year period [12, 13]. It has also been observed that the majority of patients failed to recognise 
the early signs and symptoms of OSCC [14]. Furthermore, 30-40% of patients with a negative 
nodal status at resection eventually die from metastatic disease [15]. Thus, it is clear that the 
current diagnostic methods on which treatment modality is based on are of insufficient 
sensitivity. A non-invasive, cost effective and rapid method for early diagnosis of OSCC is, 
therefore, a priority. 
 Tumour markers are substances found in blood, urine, or body tissues that can be 
elevated by the presence of one or more types of cancer. Recent research has explored the use 
of these markers to aid early diagnosis of carcinoma and they have been shown to have a wide 
range of potential applications, including screening, prognosis, and monitoring for recurrence 
or metastasis [9]. One such tumour marker is the Beta 2 Microglobulin (B2M) which was first 
described in 1968 [16]. B2M is a low molecular weight protein on the beta-chain of the human 
leukocyte antigen (HLA). It occurs physiologically in small quantities in human urine, plasma, 
and cerebrospinal fluid. It exists in two main forms, free or non-covalently linked to HLA 
antigens. The free form, which is relevant as a biomarker, is found in serum, and consists of a 
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single polypeptide chain with a single intrachain disulfide bridge with no carbohydrate content 
[16, 17]. 
 According to a recent meta-analysis on the diagnostic accuracy of serum biomarkers 
for head and neck cancer, 15 biomarkers were reported as having excellent sensitivity and 
specificity but only B2M was reported as fulfilling the accuracy criteria twice [18]. The 
increased production of B2M by carcinoma cells compared to non-neoplastic cells may be due 
to increased cell synthesis, breakdown, or both [19]. B2M levels have been reported to be 
significantly increased in individuals exposed to carcinogens, having premalignant conditions, 
at different stages of oral cancer and histological differentiation, when compared with healthy 
controls [20-22]. However, it has been shown that serum B2M is a superior diagnostic tool 
when compared to B2M level in saliva for OSCC [23]. Upregulation of B2M expression in 
tumour tissue has been associated with OSCC progression, invasion and metastasis, while the 
suppression of B2M expression in in-vitro studies using small interfering RNA (siRNA) has 
been shown to decrease cell migration and invasion [24, 25]. 
 This study had two inter-related objectives: to establish if serum B2M level can serve 
as an initial diagnostic tool to quickly determine if further investigation through biopsy is 
warranted for patients suspected of having OSCC. And if so, to propose a local reference serum 
B2M value that can be used to identify OSSC patients. A review of literature showed no studies 
on the clinical use of a B2M cut off level specific to the local Southeast Asian population, 
despite a high incidence of the disease in the region. 
The use of serum B2M level has several strengths. First, it is an inexpensive, less 
invasive technique that provides rapid results. Second, it avoids inter-observer variations 
associated with other simpler alternatives. Finally, raised B2M levels serve to increase the 
index of suspicion regarding the presence of OSCC, in the case of a negative biopsy. 
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2.0 Objectives 
 
2.1 General objective 
To study the levels of Beta 2 Microglobulin (B2M) in OSCC patients  
 
2.2 Specific objectives 
1. To determine the diagnostic utility of the B2M test in identifying OSCC patients. 
 
2. To determine the association of the Beta 2 Microglobulin level with the histological 
differentiation of OSCC. 
 
3. To determine the association of the Beta 2 Microglobulin level with the nodal status 
of OSCC patients. 
 
4. To determine the association of the Beta 2 Microglobulin level with the presence of 
distant metastasis. 
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Abstract: 
Background 
The delay in diagnosis of oral squamous cell carcinoma (OSCC) is a factor in rendering the 
poor prognosis, and recent research has explored the use of serum tumour markers such Beta 
2 Microglobulin (B2M), to aid early diagnosis. However, despite a high incidence of OSCC in 
Southeast Asia, no studies on the clinical use of B2M in the region were found. 
 
 Objectives: 
To determine if serum B2M level can serve as an initial diagnostic tool to indicate if a biopsy 
is warranted, and if so, to propose a local B2M serum reference value to identify OSSC patients 
 
Methodology: 
Twenty-one patients seen at Hospital Univesiti Sains Malaysia (HUSM) for one-year period, 
between June 2016 and June 2017, and equal number of healthy controls participated in the 
study. Apart from patient history, venous blood of approximately 5ml volume was collected 
from each subject at the pre-treatment stage and analysed by an Abbot ARCHITECT c8000 
analyser using the immunoturbidometry method.The results were analysed using ROC analysis 
and the Mann Whitney test.  
 
Results:  
Serum B2M levels showed a statistically significant increase (p<0.001) in patients compared 
to controls. The test was shown to have 90.5% sensitivity and 90.5% specificity. It was found 
to be a sensitive and specific serum tumour marker at a cut off value of 1.57 mg/l to differentiate 
cases from controls.  
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Conclusion: 
B2M is a sensitive and specific tumour marker to differentiate OSCC cases from controls. It is 
cost effective and minimally invasive, making it a potentially useful adjunct diagnostic tool in 
a high-risk patient pool. 
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Introduction 
 
 
Oral cancer is defined as a malignant neoplasm arising from oral cavity or oropharynx; 
and commonly involves sub-sites such as the anterior two thirds of the tongue, tonsils, upper 
and lower alveolar ridge, buccal mucosa, and the hard palate [1]. Oral cancer is the 6th most 
common cancer in the world but shows wide geographical variation, but a higher incidence has 
been noted in South and Southeast Asian countries such as India, Bangladesh, Taiwan, and Sri 
Lanka [2]. Squamous cell carcinoma constitutes about 90% of oral malignancies with tumours 
arising from minor salivary glands accounting for a further 5% [1].   
Local epidemiology data from the 2007 National Cancer Registry in Malaysia reported 
a total of 353 cases of oral cancer; it was ranked as the as the 21st most common cancer in the 
general population; the 17th most common among males and the 16th most common among 
females. Furthermore, only 35.4% of the 205 cases reported with staging were of stages I and 
II [3]. Oral squamous cell carcinoma (OSCC) is characterised by a high rate of metastasis, 
recurrence, and second malignancy; with a poor prognosis [4, 5]. The 5-year survival rate for 
OSCC is approximately 50% and has remained so for the past several decades [6]. This lack of 
improvement is attributed to the fact that a large number of cases are diagnosed at an advanced 
stage. The prognosis of patients with early treatment is much better, with 5-year survival rates 
as high as 80% [7]. Thus, early detection becomes vital. 
OSCC is a multifactorial disease, and the risk factors include smoking, alcohol 
consumption, betel quid chewing, poor oral hygiene and diet and nutritional deficiencies, 
especially in vitamin A, C, E, iron, selenium, folate and phosphate. Other factors such as human 
papilloma virus (HPV) infection and premalignant conditions such as leukoplakia and 
erythroplakia have also been shown to influence the pathogenesis of OSCC [1]. 
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 Clinical oral examination (COE) is the gold standard for the initial detection of 
dysplastic or malignant oral lesions at an early stage, with confirmation by biopsy and 
histopathological examination (HPE). However, a recent systematic review concluded that the 
overall performance of COE as a diagnostic method for predicting dysplasia and OSCC has 
been poor [8]. HPE is a time-consuming process, requiring several days to fix, embed and stain 
the biopsy specimen [9]. The specimen can also be affected by artefacts resulting from 
crushing, incorrect fixation and freezing [10]. Furthermore, the biopsy process is invasive in 
nature and can pose technical difficulties to the clinician when lesions are extensive, as the 
most representative areas must be selected to avoid diagnostic errors [11]. As such, the 
proportion of OSCC cases diagnosed at an early and localised stage is still <50% within a 5-
year period [12, 13]. It has also been observed that the majority of patients failed to recognise 
the early signs and symptoms of OSCC [14]. Furthermore, 30-40% of patients with a negative 
nodal status at resection eventually die from metastatic disease [15]. Thus, it is clear that the 
current diagnostic methods on which treatment modality is based on are of insufficient 
sensitivity. A non-invasive, cost effective and rapid method for early diagnosis of OSCC is, 
therefore, a priority. 
 Tumour markers are substances found in blood, urine, or body tissues that can be 
elevated by the presence of one or more types of cancer. Recent research has explored the use 
of these markers to aid early diagnosis of carcinoma and they have been shown to have a wide 
range of potential applications, including screening, prognosis, and monitoring for recurrence 
or metastasis [9]. One such tumour marker is the Beta 2 Microglobulin (B2M) which was first 
described in 1968 [16]. B2M is a low molecular weight protein on the beta-chain of the human 
leukocyte antigen (HLA). It occurs physiologically in small quantities in human urine, plasma, 
and cerebrospinal fluid. It exists in two main forms, free or non-covalently linked to HLA 
antigens. The free form, which is relevant as a biomarker, is found in serum, and consists of a 
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single polypeptide chain with a single intrachain disulfide bridge with no carbohydrate content 
[16, 17]. 
 According to a recent meta-analysis on the diagnostic accuracy of serum biomarkers 
for head and neck cancer, 15 biomarkers were reported as having excellent sensitivity and 
specificity but only B2M was reported as fulfilling the accuracy criteria twice [18]. The 
increased production of B2M by carcinoma cells compared to non-neoplastic cells may be due 
to increased cell synthesis, breakdown, or both [19]. B2M levels have been reported to be 
significantly increased in individuals exposed to carcinogens, having premalignant conditions, 
at different stages of oral cancer and histological differentiation, when compared with healthy 
controls [20-22]. However, it has been shown that serum B2M is a superior diagnostic tool 
when compared to B2M level in saliva for OSCC [23]. Upregulation of B2M expression in 
tumour tissue has been associated with OSCC progression, invasion and metastasis, while the 
suppression of B2M expression in in-vitro studies using small interfering RNA (siRNA) has 
been shown to decrease cell migration and invasion [24, 25]. 
 This study had two inter-related objectives: to establish if serum B2M level can serve 
as an initial diagnostic tool to quickly determine if further investigation through biopsy is 
warranted for patients suspected of having OSCC. And if so, to propose a local reference serum 
B2M value that can be used to identify OSSC patients. A review of literature showed no studies 
on the clinical use of a B2M cut off level specific to the local Southeast Asian population, 
despite a high incidence of the disease in the region. 
The use of serum B2M level has several strengths. First, it is an inexpensive, less 
invasive technique that provides rapid results. Second, it avoids inter-observer variations 
associated with other simpler alternatives. Finally, raised B2M levels serve to increase the 
index of suspicion regarding the presence of OSCC, in the case of a negative biopsy. 
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Materials and methods 
Case and control group selection 
This study involved a total of 42 patients from a single centre, Hospital Universiti Sains 
Malaysia (HUSM), in Kelantan, Malaysia. Subjects were made up of two groups. The ‘case’ 
group was made up of OSCC patients seen at the Otorhinolaryngology-Head and Neck Surgery 
(ORL-HNS) and Oral and Maxillofacial (OMF) Surgery clinics of HUSM, over a period of one 
year, between June 2016 and June 2017. A matching number of healthy individuals were also 
recruited to serve as the ‘control’ group. 
Eligible subjects for the case group were those with a clinically evident oral lesion, with 
HPE confirmation, and had not undergone any previous therapy/treatment for oral cancer; and 
were willing to provide written consent. Non-eligible subjects were those who had an 
autoimmune disease, who were pregnant, or were being treated for an active infection, or had 
an underlying kidney/liver disease, or previous diagnosis of another malignancy, or were 
unwilling or unable to give written consent. A total of 21 out of 30 patients satisfied the 
eligibility criteria to form the case group. The control group was made up of 21 healthy subjects 
recruited from those accompanying patients to the ORL-HNS clinic, and through 
advertisements placed in the ORL-HNS clinic inviting voluntary participation as control 
subjects. Their health status was established after a physical examination and blood screening 
to rule out pre-existing medical conditions or pregnancy.  Written informed consent was 
obtained from all subjects. 
The study protocol was reviewed and approved by the Human Research Ethics 
Committee (HREC) of USM (Study protocol code USM/JEPeM 16030139.) 
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Sample characteristics 
The ethnic composition of the case group correctly reflects the composition of the population 
of the study area with 95% being Malay, and about 5% being Chinese [26]. The control group 
had a larger representation of Chinese. There were no Indian subjects in our sample (Table 1) 
Both case and control groups were drawn from subjects aged between 18 to 80 years old, with 
the mean age among the case group being 60.6 years, with most of them within the 60-69 age 
range. The mean age among controls was lower (43.7 years). Males predominated in both case 
and control groups.  
OSCC Assessment  
Data regarding patient demographics, risk factors, histopathology and stage of disease 
were collected and recorded on a data collection sheet. All blood samples were collected 
according to a standard collection protocol. About 5mls of blood were collected in a test tube. 
The samples were centrifuged at 3000 rpm for 5 minutes after being clotted for 30 -60 minutes 
at room temperature. Aliquots of serum samples were stored at -80⁰C until analysis was 
performed. Samples were processed by an Abbot Architect c8000 analyser using the 
immunoturbidometry method for the quantitative determination of B2M. The detection limit 
was 0.046 mg/l.   
Statistical analyses 
Statistical associations were analysed using SPSS software, version 23.0. A p-value of< 
0.05 was taken to be statistically significant at a confidence level of 95%. All the numerical 
data were presented as medians (IQR) while categorical data were expressed as percentages 
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(%). Analytical statistics were done using the Mann-Whitney test and Receiving Characteristic 
Operating Curve (ROC) analysis. 
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Results 
The 21 subjects in the case group had HPE confirmed OSCC, with a staging CT done 
but no prior treatment. The most common site of presentation of primary tumour was the tongue 
(47.6%), followed by buccal mucosa (33.3%). Smoking was the highly prevalent risk factor 
for OSCC (71.4%) among the case group, as compared to betel quid chewing (23.8%). All the 
patients were in Stage IV of the disease, with moderately differentiated squamous cell 
carcinoma being the most common (52.4%) histopathological presentation (Table 2). 
 The median serum B2M level in the control group was 1.37 (0.16) mg/l and 2.56 (1.04) 
mg/l in the case group). This higher serum B2M level in the case group, as compared to the 
control group, was statistically significant (p<0.001) (Table 3). Among the 10 cases with well 
differentiated OSCC, the median serum B2M level was 2.44 (1.51) mg/l, while in 11 cases of 
moderately differentiated OSCC, the level was 2.67 (0.78) mg/l.  Increased serum B2M level 
was thus seen to be correlated with the degree of histological differentiation, although the 
difference was not statistically significant (p =0.833) (Table 4). 
 In ROC analysis, a B2M value of 1.586 mg/l was taken as a cut-off value for 
differentiating cases from controls. The recorded area under the ROC curve was 0.97. Thus, 
our study shows a 90.5% sensitivity and 90.5% specificity (Table 5).  
Median serum B2M level was 1.85 (1.67) mg/l for patients with a nodal status of N0 (4 
cases), and 2.67 (0.79) mg/l in patients with positive nodes (17 cases). However, this was not 
statistically significant (p = 0.244) (Table 6).  
Median serum B2M level was 2.50 (1.19) mg/l for patients with no distant metastasis 
(17 cases), and 2.67 (3.80) mg/l in patients positive for distant metastasis (4 cases); this, too, 
was not statistically significant (p=0.370) (Table 7) 
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Discussion 
The age distribution among the 21 case group subjects showed most of them to be 
within the 60 to 69 age range, which is consistent with Malaysian oral cancer statistics. 
Malaysian statistics also show an almost equal gender incidence; however, gender distribution 
in the study sample revealed more male subjects within the case group (61.9%). This could be 
a reflection of the localized distribution seen in Kelantan. 
The racial distribution of case subjects was mostly Malay, reflecting the racial 
composition of Kelantan state where Malays account for about 95% of the state population. 
Other minority races include those of immigrant Chinese and Indian descent [26].  
Of the three most important risk factors associated with OSCC (smoking, betel quid 
chewing and alcohol consumption), smoking was found to be more prevalent in the case group 
(71.4%) as compared to betel quid chewing (23.8%) and alcohol consumption (0%). This is 
probably due to Malay Muslim religious beliefs that prohibit alcohol consumption among our 
predominantly Malay case subjects. Consistent with global data on common OSCC subsites, 
we found that the most common site of presentation of primary tumour was the tongue (47.6%) 
followed by buccal mucosa (33.3%) [27].  
All the OSCC patients presenting to us were in stage IV of the disease, and moderately 
differentiated squamous cell carcinoma (52.4%) was the most common histopathological 
presentation, followed by well-differentiated histology (47.6%), with no cases of poorly 
differentiated disease. While it is well established that patients with OSCC tend to present late, 
the overwhelming presence of stage IV cases in our study has not been previously reported. 
We posit that the status of HUSM as a tertiary referral centre, and a centre for oncological 
management in the East Coast of Peninsular Malaysia, to be the main reason for this unusual 
finding. Patients amenable to surgery would have been treated at their respective state hospitals. 
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The local cultural preference for traditional and alternative therapy during the early stage of 
disease could be a further contributory factor. 
Serum B2M level in the OSCC group was shown to have a statistically significant 
(p<0.001) increase, and is in line with findings of previous studies, although the mechanism of 
altered B2M level is not yet clearly understood [21, 22, 28, 29]. Various postulates have been 
put forth, which include increased cellular activity, cell membrane turnover and cell division 
in malignancy [30]. Our study showed 90.5% sensitivity and 90.5% specificity by ROC 
analysis, consistent with other studies [23, 31]. B2M was also found to have good diagnostic 
test accuracy measurements, with a Positive Likelihood Ratio of 9.53, Negative Likelihood 
Ratio of 0.10, Diagnostic Odds Ratio of 95.3 and a Youden Index value of 0.81. This is in 
agreement with a recent meta-analysis which concluded that B2M was one of four (prolactin, 
glutathione, and catalase) biomarkers with the highest diagnostic test accuracy [18].  
Serum B2M levels were seen to correlate with a worsening degree of histological 
differentiation, although this was not statistically significant. This finding is incongruent with 
other studies; the possible reasons include a small sample size and the absence of poorly 
differentiated histology among our patient pool [32]. Median serum B2M levels were also not 
significantly increased for variables of nodal status and distant metastasis, unlike in tissue 
studies, where the association of B2M expression with progression and metastasis of OSCC 
lesions was statistically significant [24, 25]. Other serum based studies, however, did not 
analyse those variables [21-23, 28, 29, 31], thus ruling out comparisons. 
It is therefore apparent that B2M is a sensitive and specific serum tumour marker at a 
cut off value of 1.57 mg/l to differentiate cases from controls, for a case group consisting of 
primarily Malay subjects. This can serve as an initial reference value for countries in the region 
with large Malay populations such as Malaysia and neighbouring Indonesia, since currently 
none exists. 
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The utility of B2M serum tumour marker as a singular screening tool is diminished 
because an elevated level has also been reported in cases of haematological malignancies, 
tumours of the breast, lung, and gastrointestinal and genitourinary tracts [29]. In addition, its 
role as a serum prognostic marker has yet to be verified conclusively in literature.  
However, it can serve well an adjunct diagnostic tool for the early diagnosis of OSCC, 
and to determine if a biopsy is warranted. Its utility lies in the fact that it is cost effective, 
minimally invasive, and yields results within a minimal timespan, as compared to more 
expensive alternatives such as an oral brush biopsy. Furthermore, it avoids inter-observer 
variation associated with other protocols such as fluorescence spectroscopy and toluidine blue 
staining [33]. Most importantly, raised B2M levels serve to increase the index of suspicion 
regarding the presence of OSCC, in the case of a negative biopsy. 
Conclusion 
The early diagnosis of oral squamous cell carcinoma (OSCC) is of paramount 
importance and the first step to achieving this is the further development of rapid, less invasive 
and accurate methods of screening and diagnosis. B2M holds great promise, when used as an 
adjunct with other recently developed techniques because of its low cost, minimally-invasive 
nature and quick availability of results. 
Limitations 
Our study has a few limitations: first, the sample size was small; second, our findings 
may have limited external validity due to it being localised to a single centre and was confined 
to a largely Malay sample. Finally, all of our patients presented an advanced stage of disease. 
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